Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
NCT06398587 · OHSU Knight Cancer Institute · PHASE2 · withdrawn · last registry update 2024-07-19 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor withdrawal” | Open Targets' class: business administrative | Registry record, OHSU Knight Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLK1 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
No results, stops or Phase 3 starts on the same target in that window.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision